港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Prosperous Printing Company Limited 萬 里 印 刷 有 限 公 司 訂立優惠券服務合作備忘錄 本 公 佈 由 萬 里 印 刷 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 本 公 司 股 東（「股 東」）及 有 意 投 資 者 提 供 本 集 團 的 最 新 業 務 發 展 更 新 資 料。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，於2026年3月23日（交 易 時 段 後），Jade View Limited（「Jade View」）與 米 索 飛（香 港）有 限 公 司（「米索飛」）（統 稱「訂約方」）訂 立 優 惠 券 服 務 合 作 備 忘 錄（「備忘錄」）。根 據 ...

Core Viewpoint - Lianhua Supermarket (00980) expects a significant reduction in net loss attributable to shareholders for the year ending December 31, 2025, compared to the net loss for the year ending December 31, 2024, primarily due to strategic adjustments, sale of subsidiary equity, and optimized resource allocation [1] Financial Performance - The company anticipates a net loss of approximately RMB 359 million for the year ending December 31, 2024 [1] - The expected reduction in net loss for the year ending December 31, 2025, is projected to be between 35% to 55% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司） （股份代碼：3983） 公告 委託管理富島化工 本次交易 董事會宣佈，於2026年2月28日，本公司、中海石油煉化及富島化工簽訂委託管理協議， 據此，本公司委託中海石油煉化對富島化工日常生產經營進行管理。委託管理協議期限 由2026年3月1日起至2029年2月28日止。 本次交易的原因及好處 鑒於中海石油煉化的全資附屬公司東方石化為富島化工的主要原料供應商，其具備產 業協同優勢，且在富島化工降本增效方面處於更有利位置。此外，東方石化在丙烯腈等 化工產品的生產經營方面擁有先進、成熟且廣泛的能力與經驗。為了進一步推動資源配 置與管理的優化，以及提升富島化工的經營效率，各方已同意訂立本次交易。 上市規則的涵義 於本公告日期，中國海油為本公司的控股股東，中海石油煉化為中國海油的全資附屬公 司。因此，根據上市規則第14A.07條，中海石油煉化為本公司的關連人士。此外， ...

Core Viewpoint - Jiangsu Xinneng (603693.SH) plans to deregister its subsidiary Jiangsu Xinneng Haoyou New Energy Development Co., Ltd., which is considered an affiliated transaction due to the ownership stakes held by Jiangsu Guoxin Gaoyou Thermal Power Co., Ltd. and Boteng International Investment and Trade Co., Ltd. [1] Group 1 - The deregistration of the subsidiary and the decision to cease participation in the Gaoyou city-wide rooftop distributed photovoltaic project will help the company optimize resource allocation, reduce management costs, and enhance operational efficiency [1] - Upon completion of the deregistration, Xinneng Haoyou will no longer be included in the company's consolidated financial statements, and this action is not expected to have a significant adverse impact on the company's financial condition or operating results [1] - The decision does not harm the interests of the company or its shareholders, particularly minority shareholders [1]

Group 1 - The core point of the article is that Shijiazhuang Pharmaceutical Group announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for 230 million yuan, after which the company will no longer hold any shares in the firm [1] - The transaction price was slightly above the assessed value of 226 million yuan, which was based on an independent evaluation with a total equity value of 753 million yuan for Guoxin Huijin as of June 30, 2025 [1] - Guoxin Huijin's main business is in the full media communication sector, specifically mobile financial information services, which is not a core area for Shijiazhuang Pharmaceutical [1] Group 2 - The financial data indicates that Guoxin Huijin is projected to generate revenue of 42.52 million yuan in 2025, with a net loss of 26.94 million yuan, including a loss of 15.72 million yuan in the second half of the year [1] - The purpose of the sale is to optimize resource allocation and focus on the core pharmaceutical business, with proceeds intended to supplement the daily operating funds of Shijiazhuang Pharmaceutical [1] - The company expects to record a loss of approximately 15 million yuan from this transaction, calculated as the difference between the transaction price and the book value of the investment [1]

Core Viewpoint - The company Shiyao Group (01093) announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its resource allocation and financial structure [1] Group 1 - The seller, Shiyao Innovation Pharmaceutical Co., Ltd., is a non-wholly owned subsidiary of Shiyao Group [1] - The transaction is expected to help the seller concentrate on its core business and reduce operational risks, leading to high-quality development [1] - The target company primarily operates a full-media communication business, which is not part of the seller's core operations [1]

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group (石药集团), has announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its financial structure [1]. Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1]. - The transaction is based on a comprehensive consideration of the seller's actual development status [1]. - The sale is expected to help optimize the seller's resource allocation and financial structure, allowing for a focus on core business and reduction of operational risks [1]. Group 2 - The target company primarily operates a full-media communication business platform, which is not part of the seller's core business [1]. - After the completion of the sale, the seller and the group will no longer hold any equity in the target company [1]. - This move is anticipated to contribute to the overall benefit of the group and facilitate high-quality development [1].

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, aiming to optimize resource allocation and focus on core business operations [1] Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1] - The transaction is expected to enhance the seller's financial structure and reduce operational risks [1] - The target company primarily operates in the full media communication business, which is not part of the seller's core operations [1] Group 2 - The completion of the sale will result in the seller and the group no longer holding any equity in the target company [1] - The decision to sell was based on a comprehensive assessment of the seller's actual development status [1] - This move is anticipated to facilitate high-quality development for the seller and benefit the overall group [1]

Group 1 - The company, Sailong Pharmaceutical Group Co., Ltd., will hold its third extraordinary general meeting of shareholders on March 5, 2026, in Changsha, Hunan Province, combining on-site and online voting [1][3][5] - The meeting will discuss a temporary proposal to continue the public transfer of the equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., which was submitted by the controlling shareholder, Hainan Yayi Gongying Technology Partnership [2][4][9] - The company has set the record date for shareholders to attend the meeting as March 2, 2026 [6][7] Group 2 - The company will provide a network voting platform for shareholders through the Shenzhen Stock Exchange, allowing them to vote online during specified times on March 5, 2026 [5][17][25] - The company has previously attempted to publicly transfer 100% of the equity of Hunan Sailong Biopharmaceutical Co., Ltd. but did not find qualified buyers during the initial offering period [33][34] - The starting price for the upcoming public transfer of the subsidiary's equity will be set at 78.255 million yuan, reflecting a 10% reduction from the previous offering price [34][44]

Group 1 - The company plans to publicly transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., to optimize resource allocation and improve operational efficiency [2][4] - The initial public offering price for the equity was set at RMB 86.95 million, based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [3][9] - The first public offering period ended without attracting any qualified buyers, leading the company to reduce the offering price by 10% to RMB 78.255 million for the next round of bidding [4][3] Group 2 - The subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., was established on July 19, 2017, with a registered capital of RMB 104.54 million and operates in drug production and sales [8] - The financial assessment indicated that the market value of the subsidiary's total equity was RMB 86.9439 million as of September 30, 2025 [9][10] - The company has completed a capital increase for the subsidiary, raising its registered capital from RMB 55 million to RMB 104.54 million as of January 14, 2026 [13] Group 3 - The board of directors approved the proposal for the public transfer of the subsidiary's equity, which will be submitted for shareholder approval [4][43] - The company aims to use the proceeds from the equity transfer to support its operational development, aligning with its strategic growth plans [15] - The company retains the right to terminate the transfer process if no qualified buyers are found after subsequent rounds of bidding [4][5]